Tonix Pharmaceuticals (TNXP) Competitors

Neoleukin Therapeutics (NASDAQ:NLTX) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking.

Does the media refer more to NLTX or TNXP?

In the previous week, Neoleukin Therapeutics and Neoleukin Therapeutics both had 1 articles in the media. Neoleukin Therapeutics' average media sentiment score of 0.00 beat Tonix Pharmaceuticals' score of -0.29 indicating that Neoleukin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neoleukin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tonix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher earnings and valuation, NLTX or TNXP?

Neoleukin Therapeutics has higher earnings, but lower revenue than Tonix Pharmaceuticals. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	-5.34
Tonix Pharmaceuticals	$7.77M	5.66	-$116.66M	-$52.74	0.00

Does the MarketBeat Community favor NLTX or TNXP?

Tonix Pharmaceuticals received 290 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 61.04% of users gave Tonix Pharmaceuticals an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.

Company	Underperform	Outperform
Neoleukin Therapeutics	Outperform Votes 50 45.87%	Underperform Votes 59 54.13%
Tonix Pharmaceuticals	Outperform Votes 340 61.04%	Underperform Votes 217 38.96%

Do insiders & institutionals believe in NLTX or TNXP?

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more risk & volatility, NLTX or TNXP?

Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.

Do analysts prefer NLTX or TNXP?

Tonix Pharmaceuticals has a consensus target price of $53.50, indicating a potential upside of 22,617.62%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tonix Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is NLTX or TNXP more profitable?

Neoleukin Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Neoleukin Therapeutics' return on equity of -37.22% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Tonix Pharmaceuticals	-1,197.86%	-163.95%	-118.88%

Summary

Tonix Pharmaceuticals beats Neoleukin Therapeutics on 9 of the 16 factors compared between the two stocks.